Market capitalization | $90.00k |
Enterprise Value | $1.25b |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.60 |
P/S ratio (TTM) P/S ratio | 0.00 |
P/B ratio (TTM) P/B ratio | 0.00 |
Revenue growth (TTM) Revenue growth | -7.38% |
Revenue (TTM) Revenue | $481.58m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Invitae Corp.:
1 Analyst has issued a forecast Invitae Corp.:
Sep '23 |
+/-
%
|
||
Revenue | 482 482 |
7%
7%
|
|
Gross Profit | 131 131 |
34%
34%
|
|
EBITDA | -352 -352 |
46%
46%
|
EBIT (Operating Income) EBIT | -498 -498 |
35%
35%
|
Net Profit | -1,441 -1,441 |
55%
55%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Kenneth Knight |
Founded | 2010 |
Website | www.invitae.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.